The Vaughan, Ontario-based company expects revenue to climb between 5% and 7% on a constant currency basis over the next two years. According to the company's guidance, revenue for 2026 is projected to hit $5.38 billion to $5.48 billion, aligning closely with analyst expectations of $5.39 billion. Management also targets a significant jump in adjusted EBITDA, aiming for $1 billion to $1.05 billion by the end of that period, up from an estimated $858 million in 2025.
In section Market Quotes
Bausch + Lomb Targets $5.4B Revenue by 2026 After Q4 Sales Beat
Bausch + Lomb has issued a bullish multi-year outlook following a fourth-quarter revenue surge, forecasting sales to reach as high as $5.48 billion by 2026. While the eye-health specialist outperformed top-line expectations behind double-digit growth in its pharmaceutical division, a heavy tax provision widened its net loss during the final months of the year.
Pharma Gains Drive Top-Line Growth
Total revenue for the quarter rose to $1.41 billion, surpassing the $1.39 billion consensus. This growth was fueled by consistent performance across all primary business units, particularly within the specialized medicine category. Performance highlights include:
- The Pharmaceuticals division led the way with a 14% increase to $378 million.
- Vision Care, the company’s largest segment, grew 8% to $778 million.
- Surgical revenue climbed 8% to reach $249 million.
Comments (0)
No comments yet. Be the first!